- Home
- ZTR vs MRVI Comparison
ZTR vs MRVI Comparison
Compare ZTR & MRVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ZTR
- MRVI
- Stock Information
- Founded
- ZTR 1988
- MRVI 2014
- Country
- ZTR Australia
- MRVI United States
- Employees
- ZTR N/A
- MRVI N/A
- Industry
- ZTR Investment Managers
- MRVI Biotechnology: Pharmaceutical Preparations
- Sector
- ZTR Finance
- MRVI Health Care
- Exchange
- ZTR Nasdaq
- MRVI Nasdaq
- Market Cap
- ZTR 350.0M
- MRVI 376.2M
- IPO Year
- ZTR N/A
- MRVI 2020
- Fundamental
- Price
- ZTR $6.47
- MRVI $3.14
- Analyst Decision
- ZTR
- MRVI Hold
- Analyst Count
- ZTR 0
- MRVI 9
- Target Price
- ZTR N/A
- MRVI $4.54
- AVG Volume (30 Days)
- ZTR 219.4K
- MRVI 1.7M
- Earning Date
- ZTR 01-01-0001
- MRVI 11-06-2025
- Dividend Yield
- ZTR 12.09%
- MRVI N/A
- EPS Growth
- ZTR N/A
- MRVI N/A
- EPS
- ZTR N/A
- MRVI N/A
- Revenue
- ZTR N/A
- MRVI $219,830,000.00
- Revenue This Year
- ZTR N/A
- MRVI N/A
- Revenue Next Year
- ZTR N/A
- MRVI $7.27
- P/E Ratio
- ZTR N/A
- MRVI N/A
- Revenue Growth
- ZTR N/A
- MRVI N/A
- 52 Week Low
- ZTR $4.50
- MRVI $1.67
- 52 Week High
- ZTR $6.60
- MRVI $8.29
- Technical
- Relative Strength Index (RSI)
- ZTR 47.07
- MRVI 48.93
- Support Level
- ZTR $6.49
- MRVI $3.01
- Resistance Level
- ZTR $6.60
- MRVI $3.55
- Average True Range (ATR)
- ZTR 0.07
- MRVI 0.19
- MACD
- ZTR -0.02
- MRVI -0.06
- Stochastic Oscillator
- ZTR 26.09
- MRVI 20.31
About ZTR Virtus Total Return Fund Inc.
Virtus Total Return Fund Inc is a closed-end, diversified management investment company. Its investment objective of capital appreciation, with current income as a secondary objective. The Fund seeks to meet its objectives through a balance of equity and fixed income investments.
About MRVI Maravai LifeSciences Holdings Inc.
Maravai LifeSciences Holdings Inc is a life sciences company that provides critical products that drive the development of groundbreaking vaccines, drug therapies, cell and gene therapies, and diagnostics. The group's solutions empower research into human diseases and support the entire biopharmaceutical development process from early discovery to commercialization. Its reportable segments are Nucleic acid production and biologics safety testing. It generates a majority of its revenue from Nucleic Acid Production and focuses on the manufacturing and sale of nucleic acid products to support the needs of customers' research, and therapeutic and vaccine programs. In addition, the segment also provides research products for labeling and detecting proteins in cells and tissue samples.